Pacira BioSciences (NASDAQ:PCRX – Free Report) had its price objective cut by Royal Bank of Canada from $70.00 to $68.00 in a report published on Thursday, Benzinga reports. They currently have an outperform rating on the stock. A number of other research analysts also recently commented on PCRX. Needham & Company LLC lowered their price […]
Pacira BioSciences (NASDAQ:PCRX – Free Report) had its price target decreased by Piper Sandler from $60.00 to $50.00 in a research report released on Thursday, Marketbeat reports. Piper Sandler currently has an overweight rating on the stock. A number of other research firms have also commented on PCRX. Needham & Company LLC reduced their target […]
Pacira BioSciences (NASDAQ:PCRX – Free Report) had its target price decreased by Truist Financial from $60.00 to $55.00 in a research note published on Thursday morning, MarketBeat.com reports. Truist Financial currently has a buy rating on the stock. Several other brokerages also recently commented on PCRX. HC Wainwright lowered their price target on Pacira BioSciences […]
Pacira BioSciences (NASDAQ:PCRX – Get Free Report) had its target price cut by investment analysts at HC Wainwright from $68.00 to $63.00 in a note issued to investors on Thursday, Marketbeat reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 59.57% from the […]
Pacira BioSciences (NASDAQ:PCRX – Get Free Report) was upgraded by equities research analysts at TD Cowen from a “market perform” rating to an “outperform” rating in a note issued to investors on Thursday, Briefing.com reports. The brokerage presently has a $50.00 target price on the stock. TD Cowen’s price objective indicates a potential upside of […]